Omalizumab: tested on its own
130 studies: no other medicine in its arm. Page 2 of 2. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.
- Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis PatientsCompletedNCT00822783Phase 4How we knowReport a problem
- Non-invasive Measures of Effects of Xolair in AsthmaTerminatedNCT00784485Phase 4How we knowReport a problem
- Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled CorticosteroidsCompletedNCT00691873Phase 4How we knowReport a problem
- The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood BasophilsStatus unknownNCT00673218Phase 4How we knowReport a problem
- The Effect of Xolair (Omalizumab) on Allergy Blood CellsCompletedNCT00657891Phase 4How we knowReport a problem
- A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal TherapyCompletedNCT00639691Phase 4How we knowReport a problem
- Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic SinusitisWithdrawnNCT00603785Phase 4How we knowReport a problem
- Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaCompletedNCT00546143Phase 4How we knowReport a problem
- Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma PatientsCompletedNCT00482508Phase 3How we knowReport a problem
- Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic AsthmaCompletedNCT00482248Phase 3How we knowReport a problem
- A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)CompletedNCT00401596Phase 3How we knowReport a problem
- Safety and Efficacy Study of Omalizumab Given Prior to ImmunotherapyCompletedNCT00329381Phase 4How we knowReport a problem
- Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With OmalizumabTerminatedNCT00287378Not applicableHow we knowReport a problem
- Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy AsthmaStatus unknownNCT00286416Not applicableHow we knowReport a problem
- Omalizumab to Treat Hyper-IgE (Job's) SyndromeCompletedNCT00260702Phase 1How we knowReport a problem
- A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced AsthmaWithdrawnNCT00242359Phase 4How we knowReport a problem
- Study of Omalizumab in Moderate to Severe Bronchial AsthmaCompletedNCT00232050Phase 3How we knowReport a problem
- Soluble CD23 Expression in Asthma Patients Treated With OMATerminatedNCT00226200Not applicableHow we knowReport a problem
- Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.CompletedNCT00219323Phase 3How we knowReport a problem
- Effect of Xolair on Airway HyperresponsivenessStatus unknownNCT00208234Phase 4How we knowReport a problem
- Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe AsthmaCompletedNCT00180011Phase 2/3How we knowReport a problem
- Non-invasive Ways to Evaluate Lung Disease After Treatment With XolairCompletedNCT00139152Phase 4How we knowReport a problem
- The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled AsthmaCompletedNCT00133042Phase 4How we knowReport a problem
- Effect of Anti-IgE in Chronic UrticariaCompletedNCT00130234Phase 2How we knowReport a problem
- Xolair in Patients With Chronic SinusitisCompletedNCT00117611Phase 4How we knowReport a problem
- A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic AsthmaCompletedNCT00109200Phase 3How we knowReport a problem
- An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143gCompletedNCT00109187Phase 3How we knowReport a problem
- A Safety and Efficacy Study of Xolair in Peanut AllergyTerminatedNCT00086606Phase 2How we knowReport a problem
- Omalizumab to Treat Eosinophilic GastroenteritisCompletedNCT00084097Phase 2How we knowReport a problem
- Efficacy and Safety of Omalizumab in Patients With Severe Persistent AsthmaCompletedNCT00046748Phase 3How we knowReport a problem